Concomitant teriparatide plus raloxifene for the treatment of postmenopausal osteoporosis: Results from a randomized placebo-controlled trial

被引：0
|
作者：
Krege, JH
Omizo, M
Schwartz, EN
Eriksen, EF
Cantor, P
Wang, J
Glass, EV
Myers, SL
Deal, C
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Oregon Osteoporosis Ctr, Portland, OR USA
[3] Fdn Osteoporosis Res & Educ, Oakland, CA USA
[4] Cleveland Clin Fdn, Ctr Osteoporosis & Metab Bone Dis, Cleveland, OH 44195 USA
来源：
BONE | 2005年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [41] Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial
    Weiser, Mark
    Levi, Linda
    Burshtein, Shimon
    Hagin, Michal
    Matei, Valentin P.
    Podea, Delia
    Miclutia, Ioana
    Tiugan, Alexandru
    Pacala, Bogdan
    Grecu, Iosif Gabos
    Noy, Adam
    Zamora, Daisy
    Davis, John M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2017, 78 (07) : E758 - +
  • [42] Blackcurrants Reduce the Risk of Postmenopausal Osteoporosis: A Pilot Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Nosal, Briana M.
    Sakaki, Junichi R.
    Macdonald, Zachary
    Mahoney, Kyle
    Kim, Kijoon
    Madore, Matthew
    Thornton, Staci
    Tran, Thi Dong Binh
    Weinstock, George
    Lee, Elaine Choung-Hee
    Chun, Ock K.
    NUTRIENTS, 2022, 14 (23)
  • [43] Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis
    Pak, CYC
    Sakhaee, K
    Bell, NH
    Licata, A
    Johnston, C
    Rubin, B
    Bonnick, S
    Piziak, V
    Graham, H
    Ballard, J
    Berger, R
    Fears, W
    Breslau, N
    Rubin, C
    AdamsHuet, B
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (02) : 160 - 168
  • [44] Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial
    Meltzer, EO
    Malmstrom, K
    Lu, S
    Prenner, BM
    Wei, LX
    Weinstein, SF
    Wolfe, JD
    Reiss, TF
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (05) : 917 - 922
  • [45] Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial
    Labad, Javier
    Martorell, Lourdes
    Huerta-Ramos, Elena
    Cobo, Jesus
    Vilella, Elisabet
    Rubio-Abadal, Elena
    Garcia-Pares, Gemma
    Creus, Marta
    Nunez, Cristian
    Ortega, Laura
    Miquel, Eva
    Usall, Judith
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (10) : 1683 - 1689
  • [46] Effects of intranasal 17β-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women:: A randomized, placebo-controlled clinical trial
    Engin-Ustun, Yaprak
    Ustun, Yusuf
    Meydanli, M. Mutlu
    Kafkasli, Ayse
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (12) : 676 - 679
  • [47] Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
    Eastell, Richard
    Nickelsen, Thomas
    Marin, Fernando
    Barker, Clare
    Hadji, Peyman
    Farrerons, Jordi
    Audran, Maurice
    Boonen, Steven
    Brixen, Kim
    Gomes, Jose Melo
    Obermayer-Pietsch, Barbara
    Avramidis, Avraam
    Sigurdsson, Gunnar
    Glueer, Claus C.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (04) : 726 - 736
  • [48] Randomized, Placebo-Controlled Trial of Biofeedback for the Treatment of Rumination
    Barba, Elizabeth
    Accarino, Anna
    Soldevilla, Alfredo
    Malagelada, Juan-R
    Azpiroz, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (07): : 1007 - 1013
  • [49] Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
    McClung, Michael R.
    O'Donoghue, Michelle L.
    Papapoulos, Socrates E.
    Bone, Henry
    Langdahl, Bente
    Saag, Kenneth G.
    Reid, Ian R.
    Kiel, Douglas P.
    Cavallari, Ilaria
    Bonaca, Marc P.
    Wiviott, Stephen D.
    de Villiers, Tobias
    Ling, Xu
    Lippuner, Kurt
    Nakamura, Toshitaka
    Reginster, Jean-Yves
    Rodriguez-Portales, Jose Adolfo
    Roux, Christian
    Zanchetta, Jose
    Zerbini, Cristiano A. F.
    Park, Jeong-Gun
    Im, KyungAh
    Cange, Abby
    Grip, Laura T.
    Heyden, Norman
    DaSilva, Carolyn
    Cohn, Dosinda
    Massaad, Rachid
    Scott, Boyd B.
    Verbruggen, Nadia
    Gurner, Deborah
    Miller, Deborah L.
    Blair, Micki L.
    Polis, Adam B.
    Stoch, S. Aubrey
    Santora, Arthur
    Lombardi, Antonio
    Leung, Albert T.
    Kaufman, Keith D.
    Sabatine, Marc S.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (12): : 899 - 911
  • [50] Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial
    Volz, HP
    Möller, HJ
    Reimann, I
    Stoll, KD
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2000, 10 (03) : 211 - 217
12345